Pathological eradication of recurrent metastatic renal cell carcinoma with sarcomatoid component by nivolumab plus ipilimumab combination therapy
Pathological eradication of recurrent metastatic renal cell carcinoma with sarcomatoid component by nivolumab plus ipilimumab combination therapy
复制标题
纳武单抗联合伊匹单抗联合治疗对复发性肉瘤样转移性肾细胞癌的病理根除
DOI：
10.1007/s13691-021-00501-2
复制
发表时间：
2021
影响因子：
0.7
通讯作者：
Takenaka Atsushi
中科院分区：
文献类型：
--
作者：
Sejima Takehiro;Masago Toshihiko;Yoshida Manabu;Nishi Takeshi;Kawabata Yasunari;Tajima Yoshitsugu;Yumioka Tetsuya;Honda Masashi;Takenaka Atsushi
尽管nivolumab + ipilimumab的免疫肿瘤学联合治疗最近显示出对一线转移性肾细胞癌的显著抗肿瘤作用，但根除该疾病是极其罕见的。此外，肾细胞癌的常规治疗在肉瘤样去分化的预后不良的病理特征的情况下显示出很小的疗效。我们报告了1例腹腔镜根治性肾切除术后复发性转移性肾细胞癌伴肉瘤样成分的病例，采用纳武单抗加伊匹单抗联合治疗。一名57岁的男性患者在腹腔镜根治性肾切除术后接受了四个周期的纳武单抗加伊匹单抗和三十个周期的纳武单抗治疗局部复发和肝转移，以治疗具有肉瘤样成分的T3a肾细胞癌。免疫肿瘤治疗后，他接受了部分肝切除术治疗剩余的小肝脏病变。手术标本的病理学检查显示没有存活的癌细胞。患者在部分肝切除术后一年仍存活，无疾病迹象。我们的病例鼓励临床医生对根治性肾切除术后复发性转移性肾细胞癌患者进行二次治愈，即使切除的肾脏病理显示肉瘤样成分。
Although immuno-oncology combination therapy with nivolumab plus ipilimumab has recently shown a notable antitumor effect for first-line metastatic renal cell carcinoma, the eradication of the disease is extremely rare. Moreover, conventional treatments for renal cell carcinoma show little efficacy in the case of a poor prognostic pathological feature of sarcomatoid dedifferentiation. We report a case of pathological eradication of recurrent metastatic renal cell carcinoma with sarcomatoid component after laparoscopic radical nephrectomy by nivolumab plus ipilimumab combination therapy. A 57-year-old male patient received four cycles of nivolumab plus ipilimumab and thirty cycles of nivolumab for local recurrence and liver metastasis after laparoscopic radical nephrectomy for T3a renal cell carcinoma with sarcomatoid component. He underwent partial hepatectomy for the remaining small hepatic lesion after immuno-oncology therapy. Pathology of the surgical specimen showed no viable cancer cells. The patient was alive with no evidence of disease a year after partial hepatectomy. Our case encourages clinicians to achieve a second cure for patients with recurrent metastatic renal cell carcinoma after radical nephrectomy even though the resected kidney pathology showed sarcomatoid component.
DOI：
10.1016/j.juro.2009.07.049
发表时间：
2009-11
期刊：
The Journal of urology
影响因子：
--
作者：
Shuch B;Said J;La Rochelle JC;Zhou Y;Li G;Klatte T;Kabbinaavar FF;Pantuck AJ;Belldegrun AS
通讯作者：
Belldegrun AS
DOI：
10.1016/s1470-2045(12)70559-4
发表时间：
2013-02
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Heng DY;Xie W;Regan MM;Harshman LC;Bjarnason GA;Vaishampayan UN;Mackenzie M;Wood L;Donskov F;Tan MH;Rha SY;Agarwal N;Kollmannsberger C;Rini BI;Choueiri TK
通讯作者：
Choueiri TK